- Home
- JVA vs APLM Comparison
JVA vs APLM Comparison
Compare JVA & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVA
- APLM
- Stock Information
- Founded
- JVA 1971
- APLM 2016
- Country
- JVA United States
- APLM United States
- Employees
- JVA N/A
- APLM N/A
- Industry
- JVA Packaged Foods
- APLM Blank Checks
- Sector
- JVA Consumer Staples
- APLM Finance
- Exchange
- JVA Nasdaq
- APLM Nasdaq
- Market Cap
- JVA 19.5M
- APLM 6.9M
- IPO Year
- JVA 2005
- APLM N/A
- Fundamental
- Price
- JVA $4.41
- APLM $6.56
- Analyst Decision
- JVA
- APLM
- Analyst Count
- JVA 0
- APLM 0
- Target Price
- JVA N/A
- APLM N/A
- AVG Volume (30 Days)
- JVA 239.9K
- APLM 6.5K
- Earning Date
- JVA 06-13-2025
- APLM 08-13-2025
- Dividend Yield
- JVA N/A
- APLM N/A
- EPS Growth
- JVA 856.08
- APLM N/A
- EPS
- JVA 0.65
- APLM N/A
- Revenue
- JVA $84,651,329.00
- APLM $198,000.00
- Revenue This Year
- JVA N/A
- APLM $415.15
- Revenue Next Year
- JVA N/A
- APLM N/A
- P/E Ratio
- JVA $6.58
- APLM N/A
- Revenue Growth
- JVA 15.86
- APLM N/A
- 52 Week Low
- JVA $1.50
- APLM $4.47
- 52 Week High
- JVA $9.93
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- JVA 56.14
- APLM 53.03
- Support Level
- JVA $4.13
- APLM $6.21
- Resistance Level
- JVA $4.49
- APLM $6.80
- Average True Range (ATR)
- JVA 0.41
- APLM 0.50
- MACD
- JVA -0.01
- APLM 0.02
- Stochastic Oscillator
- JVA 54.94
- APLM 77.22
About JVA Coffee Holding Co. Inc.
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.